The purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in Germany over a 5-year period
Study Type
OBSERVATIONAL
Enrollment
550
Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics
Dermatologische Spezial- und Schwerpunktpraxis Selters
Selters, Rhineland-Palatinate, Germany
Local Institution - 0001
Selters, Germany
Proportion of patients achieving an absolute Psoriasis Area Severity Index (aPASI) score ≤ 3 at Week 24 or nearest visit
Time frame: Approximately 24 weeks after treatment initiation (data to be collected at visit nearest to this timepoint)
Effectiveness of deucravacitinib treatment measured by the number of participants who achieve an absolute Psoriasis Area Severity Index (aPASI) score ≤ 3 and ≤ 6
Time frame: 5 years
Effectiveness of deucravacitinib treatment measured by the number of participants who achieve Psoriasis Area Severity Index (PASI) 75/90/100
Time frame: 5 years
Effectiveness of deucravacitinib treatment measured by the number of participants who achieved static Physician's Global Assessment (sPGA) 0/1 and change in sPGA over time
Time frame: 5 years
Effectiveness of deucravacitinib treatment measured by body surface area (BSA) affected by psoriasis and changes in BSA from baseline and over time
Time frame: 5 years
Effectiveness of deucravacitinib treatment in sensitive body areas measured by Physician's Global Assessment (PGA) for the genital area
Time frame: 5 years
Effectiveness of deucravacitinib treatment in sensitive body areas measured by Physician's Global Assessment (PGA) for the intertriginous areas
Including but not limited to axilla, popliteal fossa, inguinal, genital, submammary, anal region
Time frame: 5 years
Effectiveness of deucravacitinib treatment in sensitive body areas measured by palmoplantar psoriasis Physician's Global Assessment (pp-PGA) for the palmoplantar area
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 5 years
Effectiveness of deucravacitinib treatment in sensitive body areas measured by target Nail Psoriasis Severity Index (NAPSI) for the nails
Time frame: 5 years
Effectiveness of deucravacitinib treatment in sensitive body areas measured by scalp-specific Physician's Global Assessment (ss-PGA) for the scalp
Time frame: 5 years
Treatment modalities and patient's satisfaction with deucravacitinib therapy measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)-9
Time frame: 5 years
Treatment modalities and patient's satisfaction with deucravacitinib therapy measured by the persistence of deucravacitinib therapy
Time from therapy initiation until discontinuation visualized using Kaplan-Meier methods
Time frame: 5 years
Treatment modalities and patient's satisfaction with deucravacitinib therapy measured by reasons for therapy discontinuation
Discontinuation of deucravacitinib defined as a treatment interruption of \>90 days with or without resumption of deucravacitinib treatment, with or without start of a follow-up therapy
Time frame: 5 years
Patient-reported outcomes measured by the Dermatology Life Quality Index (DLQI)
Time frame: 5 years
Patient-reported outcomes evaluating pruritus measured by the Itch Numeric Rating Scale (NRS)
Time frame: 5 years
Patient-reported outcomes measured by the Patient Benefit Index standard version (PBI-S)
Time frame: 5 years